Colorectal Cancer, Hepatocellular Carcinoma, Pancreatic Cancer
Conditions
Keywords
GLP1 receptor agonists, gastrointestinal cancer
Brief summary
There is a growing number of patients diagnosed with gastrointestinal cancers who are also simultaneously being treated with GLP-1 Receptor Agonists (RA)s. To date, no clinical trial data exists to establish safety and/or feasibility with use of GLP-1 RAs during chemotherapy in the metastatic setting. The goal of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and correlative analyses of combining GLP-1 RAs with standard chemotherapy in patients with metastatic pancreatic, colorectal, or hepatocellular cancers in the first-line setting.
Detailed description
The United States is facing a growing epidemic of obesity and type 2 diabetes, with over 42% of adults now classified as obese and nearly 20% of children affected by obesity. This rise has been driven by a combination of poor dietary habits, sedentary lifestyles, and social and economic factors that limit access to healthy food and healthcare. Type 2 diabetes, closely linked to obesity, affects more than 37 million Americans, with an additional 96 million adults estimated to have prediabetes. These conditions not only contribute to significant personal health burdens but also cost the U.S. economy over $370 billion annually. Disparities are evident, with higher rates among Black, Hispanic, Native American, low-income, and rural populations, largely due to systemic barriers and social determinants of health. In response, public health initiatives have promoted better nutrition, physical activity, and early intervention programs. New medications, such as GLP-1 receptor agonists, offer promising tools for weight loss and diabetes management, though their accessibility remains limited by cost and insurance coverage. Prescription data show GLP 1 RA use has exploded in recent years. For example, GLP 1 prescribing volume in the U.S. roughly tripled from early 2020 to late 2022, and annual spending jumped from $13.7 billion in 2018 to $71.7 billion by 2023 (a 62% increase in just 2022-23). Semaglutide products (Ozempic/WEGOVY) still account for the largest share of use, but Lilly's tirzepatide (Mounjaro/Zepbound) has gained market share rapidly. Uptake is broadening across age groups. Surveys indicate \ 19% of adults ages 50-64 and 8% of those ≥65 have tried GLP 1 drugs (mainly for diabetes) and prescribing to adolescents with obesity surged \ 300% in 2023 (albeit reaching only \ 0.5% of obese youth). Looking ahead, analysts project continued robust growth. One forecast estimates U.S. GLP 1 weight loss drug sales rising from about $10 B in 2024 to \ $37 B by 2030 (≈19% CAGR). Globally, GLP 1 market revenue (diabetes + obesity) could approach $130 B by 2030, with the leading agents (semaglutide and tirzepatide lines) alone generating on the order of $100 B by decade's end. This outlook reflects expanding approved uses (e.g. heart disease, potential NASH indications) and large unmet need (only \ 10-12% of U.S. adults have used GLP 1s despite over half of adults being overweight or obese). Taken together, the data indicate an unprecedented growth trajectory for GLP 1 RAs, with rapid year over year prescription gains and forecasts of very high revenues and market dominance through 2030. Similarly, pancreatic cancer and hepatocellular carcinoma are also associated with modifiable risk factors including obesity, dietary factors, and diabetes. Consequently, there is a growing number of patients diagnosed with GI cancers who are also simultaneously being treated with GLP-1 RAs. To date, no clinical trial data exists to establish safety and/or feasibility with use of GLP-1 RAs during chemotherapy in the metastatic setting. This highlights an unmet need to investigate the safety of GLP-1 RA use during chemotherapy treatment for patients with metastatic colorectal cancer, pancreatic cancer, and hepatocellular carcinoma. Furthermore, emerging evidence supports investigation of GLP-1 RAs on metabolic modulation, insulin resistance reduction, and potential anti-inflammatory effects from GLP-1 RAs in oncology settings. Both cancer types may benefit from adjunctive metabolic therapy, particularly in patients at risk of sarcopenia, cachexia, or insulin resistance. This trial aims to investigate the safety, tolerability, and efficacy of GLP-1 receptor agonist treatment in combination with standard of care (SOC) chemotherapy in patients with metastatic pancreatic, colorectal, or hepatocellular cancers in the first-line setting.
Interventions
DRUGGLP1-RA (semaglutide)
Patients will receive 6 months of weekly semaglutide; weekly subcutaneous injection; dose escalation will occur every 4 weeks with dose titration as follows: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → Maintenance at 2.4 mg or 1.7 mg pending tolerability.
Sponsors
University of Arizona
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
Masking Description
Intervention model description
Participants will be assigned to an arm based on their cancer type. The only difference between arms is the SOC treatment.
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Histological or cytological diagnosis of pancreatic adenocarcinoma or colorectal adenocarcinoma. Previous tumor tissue testing is acceptable. Please refer to the "additional HCC cohort criteria" below. * The subject has disease that is not amenable to curative-intent management (e.g., oligometastatic disease) * Measurable disease per RECIST v1.1 as determined by the investigator * Patients must be appropriate candidates for first-line, SOC treatment. * SOC treatment as defined by NCCN® guidelines or institutional standard is allowable, however, options restricted to: * Colorectal: FOLFOX or FOLIFIRI +/- bevacizumab * Pancreatic: mFOLFIRINOX * HCC: Tremelimumab/Durvalumab * Patients are eligible who received prior perioperative chemotherapy for curative intent treatment and recurred ≥ 6 months since last dose of chemotherapy. * ≥ 18 years old on day of consent * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate archival frozen or fixed tissue available from primary or metastatic site for genotypic analysis (at least 15 unstained slides and/or tumor block) * Adequate hematologic and organ function laboratory values as follows: * The ANC ≥ 1500/mm3 without colony stimulating factor support; * Platelets ≥ 75,000/mm3; * Hemoglobin ≥ 9 g/dL; * Bilirubin ≤ 1.5 ´ the ULN. For subjects with known Gilbert's disease, bilirubin ≤ 3.0 mg/dL; * Serum albumin ≥ 2.8 g/dl; * ALT and AST ≤ 3.0 ´ ULN; * Serum creatinine ≤ 1.5 ´ ULN or creatinine clearance (CrCl) ≥ 40 mL/min. For creatinine clearance estimation, the Cockcroft and Gault equation should be used: * Male: CrCl (mL/min) = (140 - age) × wt (kg) / (serum creatinine × 72); * Female: Multiply above result by 0.85; * The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document * Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control or practice abstinence during the study and for 4 months after the last dose of study drug(s); Additional Inclusion Criteria for HCC Cohort ONLY: * Histologically or radiologically confirmed hepatocellular carcinoma (per AASLD/EASL criteria) * Unresectable or advanced HCC not amenable to curative surgery or locoregional therapy. * Barcelona Clinic Liver Cancer (BCLC) stage B or C. * Child-Pugh Score Class A; or Child-Pugh Class B7 or B8 at discretion of treating physician * Patients with HBV infection, characterized by positive hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibodies (anti-HBcAb) with detectable HBV deoxyribonucleic acid (DNA) (≥10 IU/mL or above the limit of detection per local or central lab standard), must be treated with antiviral therapy, as per institutional practice to ensure adequate viral suppression (HBV DNA \<2000 IU/mL) before enrolment. Patients must remain on antiviral therapy for the duration of their participation in the EAP and for 6 months after the last dose of EAP medication. Patients who test positive for anti-hepatitis B core (HBc) with undetectable HBV DNA (\<10 IU/mL or under the limit of detection per local or central lab standard) do not require anti-viral therapy before enrolment. These participants will be tested at every cycle to monitor HBV DNA levels and initiate anti-viral therapy if HBV DNA is detected (≥10 IU/mL or above the limit of detection per local or central lab standard). HBV DNA detectable patients must initiate and remain on anti-viral therapy for time they are on the EAP and for 6 months after the last dose of EAP medication. o Note: Testing required for subjects with a known history otherwise not required. * Patients with HCV infection must have confirmed diagnosis of HCV characterized by the presence of detectable HCV ribonucleic acid (RNA) or anti-HCV antibody upon enrolment (management of this disease is per local institutional practice).
Exclusion criteria
* The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) for metastatic and/or unresectable disease. * BMI \< 25 kg/m2 * For colorectal cancer only - Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) tumors. * For colorectal cancer only - BRAF V600E mutant tumors. * A personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). * A prior hypersensitivity reaction to semaglutide or any of the excipients in WEGOVY®. Serious hypersensitivity reaction, including anaphylaxis and angioedema, have been reported with WEGOVY®. * Cachexia * Subjects on insulin. * Subjects with a history of diabetic retinopathy * Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before the first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatment * The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: o Cardiovascular disorders including: * For patients being considered for bevacizumab (or bevacizumab biosimilar) only: * Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) \> 150 mm Hg systolic or \> 100 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment; * thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter (eg, vena cava filter) within 6 months before the first dose of study treatment. * Any of the following within 6 months before the first dose of study treatment: * unstable angina pectoris; * clinically-significant cardiac arrhythmias; * stroke (including transient ischemic attack (TIA), or other ischemic event); * myocardial infarction; * GI disorders particularly those associated with a high risk of perforation or fistula formation including: * Unresolved abdominal fistula, GI perforation, bowel obstruction, intra-abdominal abscess. * Uncontrolled nausea, vomiting, or abdominal pain. * Other clinically significant disorders that would preclude safe study participation * Major surgery within 8 weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible. * Females who are known or suspected to be pregnant or lactating. Women of childbearing potential must have a negative serum pregnancy test result within screening. * Female patients planning on becoming pregnant while on study. * Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment. * Male subjects unwilling to abstain from donating sperm during treatment. * Inability to comply with self-administration of GLP-1 RA subcutaneous injections. * Subject has known sensitivity to any of the products or components to be administered during dosing. * Concurrent use of other semaglutide containing products or any other GLP-1 receptor agonist. * Diagnosis of another malignancy within 2 years before the first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy. * Subject likely to not be available to complete all protocol-required study visits or procedures and/or to comply with all required study procedures to the best of the subject and investigator's knowledge. * History or evidence of any other clinically significant disorder, condition or disease that in the opinion of the investigator, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion. Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment Emergent Adverse Events [Safety] attributed to GLP1-RA and/or its interaction with chemotherapy | Up to 6 months or at time of disease progression, whichever comes first | Safety is defined as the incidence of grade ≥3 adverse events (AEs) as defined by CTCAE v5.0, attributed to GLP-1 RA and/or its interaction with chemotherapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients who complete planned chemotherapy with concurrent GLP-1 RA without Dose Modifications or Early Termination [Tolerability] | Up to 6 months or at time of disease progression, whichever comes first | Endpoints for this outcome include: proportion of patients who complete planned chemotherapy with concurrent GLP-1 RA without unplanned dose reductions or delays \> 14 days; dose modifications; early termination: rate of early study withdrawal or discontinuation due to treatment-related adverse effects. |
| Overall Response Rate [Efficacy] | Up to 6 months or at time of disease progression, whichever comes first | Overall response rate (ORR) will be measured using the radiographic objective Response Rate as defined by RECIST v1.1 |
| Progression Free Survival [Efficacy] | Up to 6 months or at time of disease progression, whichever comes first | Progression free survival (PFS) is defined as the duration on treatment until progression as measured from start of treatment until disease progression or death from any cause. We will use 95% CI for PFS on those patients deemed efficacy eligible. |
Countries
United States
Contacts
CONTACTRachel EB Jarrett, MPH
CONTACTPrisca Zimmerman
PRINCIPAL_INVESTIGATORAaron J Scott, MD
University of Arizona
Outcome results
None listed